{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T06:52:28Z","timestamp":1780987948751,"version":"3.54.1"},"reference-count":21,"publisher":"Japanese Society for Lymphoreticular Tissue Research","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCEH","J Clin Exp Hematopathol"],"published-print":{"date-parts":[[2025]]},"DOI":"10.3960\/jslrt.25048","type":"journal-article","created":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T22:08:26Z","timestamp":1766527706000},"page":"247-252","source":"Crossref","is-referenced-by-count":2,"title":["Prognostic and immunomodulatory roles of CD30 in diffuse large B-cell                    lymphoma: a cell-of-origin- and microenvironment-dependent                    paradigm"],"prefix":"10.3960","volume":"65","author":[{"given":"Yuka","family":"Tanaka","sequence":"first","affiliation":[{"name":"Department of Hematology, Otemae Hospital, Osaka,                            Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2349","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Swerdlow                            SH,                                Campo                            E,                                Pileri                            SA                    <i>et al.<\/i> The 2016 revision of the World Health Organization                    classification of lymphoid neoplasms. Blood. 2016; 127:                    2375-2390.","DOI":"10.1182\/blood-2016-01-643569"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Sehn                            LH,                                Gascoyne                            RD. Diffuse                    large B-cell lymphoma: optimizing outcome in the context of clinical and                    biologic heterogeneity. Blood. 2015; 125: 22-32.","DOI":"10.1182\/blood-2014-05-577189"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Hu                            S,                                Xu-Monette                            ZY,                                Balasubramanyam                            A                    <i>et al.<\/i> CD30 expression defines a novel subgroup of diffuse                    large B-cell lymphoma with favorable prognosis and distinct gene expression                    signature: a report from the International DLBCL Rituximab-CHOP Consortium                    Program Study. Blood. 2013; 121: 2715-2724.","DOI":"10.1182\/blood-2012-10-461848"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Rodrigues-Fernandes                            CI,                                Abreu                            LG,                                Radhakrishnan                            R                    <i>et al.<\/i> Prognostic significance of CD30 expression in diffuse                    large B-cell lymphoma: a systematic review with meta-analysis. J Oral Pathol                    Med. 2021; 50: 587-593.","DOI":"10.1111\/jop.13208"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Bartlett                            NL,                                Hahn                            U,                                Kim                            WS                    <i>et al.<\/i> Brentuximab vedotin combination for relapsed diffuse                    large B-cell lymphoma. J Clin Oncol. 2025; 43: 1061-1072.","DOI":"10.1200\/JCO-24-02242"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Alizadeh                            AA,                                Eisen                            MB,                                Davis                            RE                    <i>et al.<\/i> Distinct types of diffuse large B-cell lymphoma                    identified by gene expression profiling. Nature. 2000; 403:                    503-511.","DOI":"10.1038\/35000501"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Slack                            GW,                                Steidl                            C,                                Sehn                            LH,                                Gascoyne                            RD. CD30                    expression in de novo diffuse large B-cell lymphoma: a population-based study                    from British Columbia. Br J Haematol. 2014; 167: 608-617.","DOI":"10.1111\/bjh.13085"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Horie                            R,                                Watanabe                            T. CD30:                    expression and function in health and disease. Semin Immunol. 1998; 10:                    457-470.","DOI":"10.1006\/smim.1998.0156"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Gorczyca                            W,                                Tsang                            P,                                Liu                            Z                    <i>et al.<\/i> CD30-positive T-cell lymphomas co-expressing CD15: an                    immunohistochemical analysis. Int J Oncol. 2003; 22: 319-324.","DOI":"10.3892\/ijo.22.2.319"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Sha                            C,                                Barrans                            S,                                Cucco                            F                    <i>et al.<\/i> Molecular high-grade B-cell lymphoma: defining a                    poor-risk group that requires different approaches to therapy. J Clin Oncol.                    2019; 37: 202-212.","DOI":"10.1200\/JCO.18.01314"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Younes                            A,                                Bartlett                            NL,                                Leonard                            JP                    <i>et al.<\/i> Brentuximab vedotin (SGN-35) for relapsed CD30-positive                    lymphomas. N Engl J Med. 2010; 363: 1812-1821.","DOI":"10.1056\/NEJMoa1002965"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Iqbal                            J,                                Shen                            Y,                                Huang                            X                    <i>et al.<\/i> Global microRNA expression profiling uncovers molecular                    markers for classification and prognosis in aggressive B-cell lymphoma. Blood.                    2015; 125: 1137-1145.","DOI":"10.1182\/blood-2014-04-566778"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Schmitz                            R,                                Wright                            GW,                                Huang                            DW                    <i>et al.<\/i> Genetics and pathogenesis of diffuse large B-cell                    lymphoma. N Engl J Med. 2018; 378: 1396-1407.","DOI":"10.1056\/NEJMoa1801445"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Chapuy                            B,                                Stewart                            C,                                Dunford                            AJ                    <i>et al.<\/i> Molecular subtypes of diffuse large B cell lymphoma are                    associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018; 24:                    679-690.","DOI":"10.1038\/s41591-018-0016-8"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Wright                            GW,                                Huang                            DW,                                Phelan                            JD                    <i>et al.<\/i> A probabilistic classification tool for genetic subtypes                    of diffuse large B cell lymphoma with therapeutic implications. Cancer Cell.                    2020; 37: 551-568.e14.","DOI":"10.1016\/j.ccell.2020.03.015"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Newman                            AM,                                Liu                            CL,                                Green                            MR                    <i>et al.<\/i> Robust enumeration of cell subsets from tissue                    expression profiles. Nat Methods. 2015; 12: 453-457.","DOI":"10.1038\/nmeth.3337"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Li                            F,                                Emmerton                            KK,                                Jonas                            M                    <i>et al.<\/i> Intracellular released payload influences potency and                    bystander-killing effects of antibody-drug conjugates in preclinical models.                    Cancer Res. 2016; 76: 2710-2719.","DOI":"10.1158\/0008-5472.CAN-15-1795"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Bai                            Y,                                He                            T,                                Zhang                            L                    <i>et al.<\/i> Prognostic value of FOXP3+ regulatory T cells in                    patients with diffuse large B-cell lymphoma: a systematic review and                    meta-analysis. BMJ Open. 2022; 12:                    e060659.","DOI":"10.1136\/bmjopen-2021-060659"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Tzankov                            A,                                Meier                            C,                                Hirschmann                            P                    <i>et al.<\/i> Correlation of high numbers of intratumoral FOXP3+                    regulatory T cells with improved survival in germinal center-like diffuse large                    B-cell lymphoma, follicular lymphoma and classical Hodgkin\u2019s lymphoma.                    Haematologica. 2008; 93: 193-200.","DOI":"10.3324\/haematol.11702"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Keane                            C,                                Vari                            F,                                Hertzberg                            M                    <i>et al.<\/i> Ratios of T-cell immune effectors and checkpoint                    molecules as prognostic biomarkers in diffuse large B-cell lymphoma: a                    population-based study. Lancet Haematol. 2015; 2: e445-e455.","DOI":"10.1016\/S2352-3026(15)00150-7"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Dave                            SS,                                Fu                            K,                                Wright                            GW                    <i>et al.<\/i> Molecular diagnosis of Burkitt\u2019s lymphoma. N Engl J Med.                    2006; 354: 2431-2442.","DOI":"10.1056\/NEJMoa055759"}],"container-title":["Journal of Clinical and Experimental Hematopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/65\/4\/65_25048\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T04:41:42Z","timestamp":1766810502000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/65\/4\/65_25048\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.3960\/jslrt.25048","relation":{},"ISSN":["1346-4280","1880-9952"],"issn-type":[{"value":"1346-4280","type":"print"},{"value":"1880-9952","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]},"article-number":"25048"}}